First Report - ID Week 2017 - October 4-8  * San Diego, CA

Conference Coverage

Treatments Reason for Hope: Promising Gram-Negative Infection Treatments in the Pipeline

Reason for Hope: Promising Gram-Negative Infection Treatments in the Pipeline

Dr McKinnell provides a summary of drugs in development for infections caused by Gram-negative bacteria, including carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae.

Treatments Safety of Clofazimine in Treating Children With Mycobacterium abscessus Infections

Safety of Clofazimine in Treating Children With Mycobacterium abscessus Infections

Clofazimine was safe and well-tolerated as part of a multidrug regimen for the treatment of children with Mycobacterium abscessus odontogenic infections.

IDWeek 2017 Managing Comorbidities and Coinfections in HIV: Interview With Rajesh T. Gandhi, MD

Managing Comorbidities and Coinfections in HIV: Interview With Rajesh T. Gandhi, MD

Rajesh T. Gandhi, MD, discusses management of coinfections, including HPV and sexually transmitted infections, in people with HIV.

IDWeek 2017 Antibiotic Stepdown Tx for Uncomplicated Gram-Negative Bloodstream Infections

Antibiotic Stepdown Tx for Uncomplicated Gram-Negative Bloodstream Infections

For uncomplicated Gram-negative bloodstream infections, oral beta-lactam therapy may be an appropriate stepdown option.

IDWeek 2017 Inappropriate Antibiotic Prescribing Rates High for Uncomplicated UTIs

Inappropriate Antibiotic Prescribing Rates High for Uncomplicated UTIs

Inappropriate prescribing of outpatient antibiotics for the treatment of uncomplicated urinary tract infections are higher than previously estimated.

IDWeek 2017 Isoniazid-Rifapentine for Latent TB Sees High Completion Rates

Isoniazid-Rifapentine for Latent TB Sees High Completion Rates

Isoniazid-rifapentine regimen sees high completion rates for latent tuberculosis infection.

IDWeek 2017 Efficacy of Continuous vs Intermittent Vancomycin for Pediatric MRSA Infections Evaluated

Efficacy of Continuous vs Intermittent Vancomycin for Pediatric MRSA Infections Evaluated

Vancomycin administered via continuous infusion was found to achieve the recommended VAN trough of 15-20mg/L faster and with less risk of adverse events compared to administration via intermittent infusion.

IDWeek 2017 Incidence of STI in PrEP Users Who Report Alcohol/Drug Use

Incidence of STI in PrEP Users Who Report Alcohol/Drug Use

The aim of this study was to identify and characterize PrEP patients who remain at high risk for HIV as demonstrated by STI diagnosis after starting PrEP.

IDWeek 2017 Infant Gut Microbiome Altered by Maternal Antibiotic Use

Infant Gut Microbiome Altered by Maternal Antibiotic Use

Mothers' use of antibiotics affects infant gut composition up to a month later.

IDWeek 2017 Safety, Efficacy of TAF vs TDF in HIV+ Adults Stratified by Race

Safety, Efficacy of TAF vs TDF in HIV+ Adults Stratified by Race

Among HIV-infected, virologically suppressed black adults, FTC/TAF showed improvements in renal and bone safety compared to FTC/TDF.

Hepatitis HIV/HCV Coinfections: Barriers to Effective Treatment

HIV/HCV Coinfections: Barriers to Effective Treatment

Only a small percentage of people with HIV/HCV coinfection receive treatment for hepatitis C.

IDWeek 2017 Frequent Syphilis Screening Necessary for High-Risk Populations

Frequent Syphilis Screening Necessary for High-Risk Populations

In 2004, syphilis screening guidelines were changed to recommend rapid plasma regain testing every 3 to 6 months.

IDWeek 2017 Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

Three months of rifapentine + isoniazid using directly observed therapy resulted in a higher completion rate and no loss of follow-up for latent tuberculosis.

IDWeek 2017 Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

Ibalizumab may be a valuable option in patients with multidrug-resistant HIV.

IDWeek 2017 Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

Examining the barriers to co-use of hormonal contraceptives and antiretroviral therapy in women with HIV.

IDWeek 2017 Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

Abacavir ART Does Not Increase Risk for Myocardial Infarction or CVD

Abacavir-containing antiretroviral therapy does not appear to confer an increased risk for myocardial infarction or coronary artery disease.

IDWeek 2017 The T2Candida Panel Has Decreased Time to Therapy Initiation for Candidemia

The T2Candida Panel Has Decreased Time to Therapy Initiation for Candidemia

Antimicrobial stewardship traditionally focuses on optimal use of antibacterial agents, not antifungal therapy.

IDWeek 2017 Efficacy of Procalcitonin-Guided Antimicrobial Stewardship Initiative for Diagnosing Pneumonia

Efficacy of Procalcitonin-Guided Antimicrobial Stewardship Initiative for Diagnosing Pneumonia

Implementation of a procalcitonin diagnostic algorithm improves diagnostic yield and reduces hospital length of stay in bacterial pneumonia.

IDWeek 2017 Ribaxamase May Prevent Opportunistic Infections During IV β-lactam Treatment

Ribaxamase May Prevent Opportunistic Infections During IV β-lactam Treatment

SYN-004, ribaxamase, is an oral B-lactamase medication to be combined with intravenous β-lactam antibiotics to prevent disruption of the gut microbiome.

IDWeek 2017 Minorities With Low Income and Poor Education Receive Lower Uptake of PCV13

Minorities With Low Income and Poor Education Receive Lower Uptake of PCV13

Multiple disparities exist in rates of adult vaccination for 13-valent pneumococcal conjugate vaccine.

Upcoming Meetings

Sign Up for Free e-newsletters